Clarus Therapeutics Reports First Quarter 2022 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall Street indexes fall, with Iran and earnings season in focus
- Oil settles 1% higher as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
Clarus Therapeutics (CRXT) Misses Q1 EPS by 21c
May 16, 2022 4:12 PM EDTClarus Therapeutics (NASDAQ: CRXT) reported Q1 EPS of ($0.61), $0.21 worse than the analyst estimate of ($0.40). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.5 million.
For earnings history and earnings-related data on Clarus Therapeutics (CRXT) click here.
... More